Encompass Health Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $EHC in the last 7 days.
Encompass Health (EHC) reported Q2 revenue of $1.597B, up 9.6%, and adjusted EPS of $1.55, up 10.7%. The company raised full-year guidance for revenue, EBITDA, and EPS. It also increased its stock repurchase authorization to $1B. Patient volume and revenue per discharge grew, but free cash flow fell due to higher capital spending. Long-term debt rose to $2.598B.
Encompass Health (EHC) reported adjusted EPS of $1.55, raised its 2026 outlook, and increased its share buyback program to $1B. The company plans to open new hospitals and add beds, signaling confidence in long-term demand. Analysts project $7.9B revenue and $806.1M earnings by 2029, a 22% upside from current prices. Labor shortages remain a key risk.
Encompass Health Corp (EHC) Chief Accounting Officer Andrew Price sold 5,211 shares at $120.93 each, totaling $630,000, leaving him with 69,483 shares. This follows a year of insider selling with no buying, raising questions about near-term prospects. The stock is fairly valued, trading 4.8% above its GF Value estimate.
Recent EHC coverage spans financial news, earnings and insider activity.
In the last 30 days, EHC insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.2M). The most active reporter was Darby John Patrick, EVP, Gen Counsel & Secretary, with 1 filing.
Guidance lift suggests stronger demand and pricing power, likely supporting the stock price in the near term.
Earnings beat and higher guidance support a bullish outlook, while the larger buyback adds upside potential.
The insider sale represents a modest $630k divestment by a senior executive, adding to a pattern of net insider selling at the company.
The insider sale may signal personal cash needs or lack of confidence, potentially pressuring the stock short term.
Insider sale of modest size may signal slight negative sentiment but unlikely to move price materially.
AlphAI scores every news story that mentions EHC with an AI model for sentiment and relevance, and aggregates insider trades from Encompass Health Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Encompass Health (EHC) reported Q2 revenue of $1.597B, up 9.6%, and adjusted EPS of $1.55, up 10.7%. The company raised full-year guidance for revenue, EBITDA, and EPS. It also increased its stock repurchase authorization to $1B. Patient volume and revenue per discharge grew, but free cash flow fell due to higher capital spending. Long-term debt rose to $2.598B.
2 min readEncompass Health (EHC) reported adjusted EPS of $1.55, raised its 2026 outlook, and increased its share buyback program to $1B. The company plans to open new hospitals and add beds, signaling confidence in long-term demand. Analysts project $7.9B revenue and $806.1M earnings by 2029, a 22% upside from current prices. Labor shortages remain a key risk.
2 min readEncompass Health Corp (EHC) Chief Accounting Officer Andrew Price sold 5,211 shares at $120.93 each, totaling $630,000, leaving him with 69,483 shares. This follows a year of insider selling with no buying, raising questions about near-term prospects. The stock is fairly valued, trading 4.8% above its GF Value estimate.
1 min readPrice Andrew L (Chief Accounting Officer) sold 5,211 shares of Encompass Health Corp (EHC) at $120.93 ($0.63M total) on 2026-08-31.
1 min readDarby John Patrick (EVP, Gen Counsel & Secretary) sold 4,858 shares of Encompass Health Corp (EHC) at $121.09 ($0.59M total) on 2026-08-31.
1 min readEncompass Health Corporation (EHC) is expanding capacity to address high occupancy and meet demand, targeting 6-8% discharge growth. Plans include 6-10 new hospitals annually, 150-200 beds at existing sites, and small-format facilities starting 2027. North Carolina's repeal of Certificate of Need requirements is a long-term catalyst. EHC has financial flexibility with 1.9X net leverage and a $1 billion share repurchase program, but faces labor and reimbursement risks.
2 min readEncompass Health (EHC) has gained 13.9% over six months, outperforming its industry. The company, with a $12B market cap, operates 176 inpatient rehab hospitals. Its forward P/E is 18.92X, below the industry average. Earnings estimates for 2026 are $6.04 per share, up 10.8% YoY, with revenue expected at $6.5B, up 8.8% YoY. EHC has beaten earnings estimates for four consecutive quarters, with an average surprise of 6.8%. The company is expanding capacity and improving staff retention, but faces r
3 min readEncompass Health reported revenue growth of about 10% to $1.6 billion and raised full-year guidance, along with dividend and $1 billion buyback authorization, after which shares rose near a 52-week high. On the same day, CFO Scott Coltharp trimmed his stake, selling a smaller portion than CEO Mark Tarr. Investors may view the sales alongside the earnings update.
3 min readEncompass Health CEO Mark J. Tarr sold about 173,148 shares on Aug. 10, 2026, for about $21.7 million, per an SEC Form 4. The weighted-average sale price was $125.47 and the Aug. 10 close was $125.81. His direct holdings fell about 39% to 267,814 shares. Encompass Health’s market cap was about $12.5 billion.
5 min readEncompass Health Corp. (NYSE: EHC) priced a private offering of $100 million additional 5.875% senior notes due 2034 at 98.75% of principal, reopening its May 2026 issue. Interest is payable semiannually starting Dec. 1, 2026. Net proceeds will repay amounts under its senior secured revolving credit facility. Expected close Aug. 13, 2026.
2 min read
